Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.
OBJECTIVE
To evaluate factors associated with successful use of continuous glucose monitoring (CGM) among participants with intensively treated type 1 diabetes in the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Clinical Trial.


METHODS
The 232 participants randomly assigned to the CGM group (165 with baseline A1C >or=7.0% and 67 with A1C <7.0%) were asked to use CGM on a daily basis. The associations of baseline factors and early CGM use with CGM use >or=6 days/week in the 6th month and with change in A1C from baseline to 6 months were evaluated in regression models.


RESULTS
The only baseline factors found to be associated with greater CGM use in month 6 were age >or=25 years (P < 0.001) and more frequent self-reported prestudy blood glucose meter measurements per day (P < 0.001). CGM use and the percentage of CGM glucose values between 71 and 180 mg/dl during the 1st month were predictive of CGM use in month 6 (P < 0.001 and P = 0.002, respectively). More frequent CGM use was associated with a greater reduction in A1C from baseline to 6 months (P < 0.001), a finding present in all age-groups.


CONCLUSIONS
After 6 months, near-daily CGM use is more frequent in intensively treated adults with type 1 diabetes than in children and adolescents, although in all age-groups near-daily CGM use is associated with a similar reduction in A1C. Frequency of blood glucose meter monitoring and initial CGM use may help predict the likelihood of long-term CGM benefit in intensively treated patients with type 1 diabetes of all ages.
jdrfapp@jaeb.org
Beck
Roy W
RW
Buckingham
Bruce
B
Miller
Kellee
K
Wolpert
Howard
H
Xing
Dongyuan
D
Block
Jennifer M
JM
Chase
H Peter
HP
Hirsch
Irl
I
Kollman
Craig
C
Laffel
Lori
L
Lawrence
Jean M
JM
Milaszewski
Kerry
K
Ruedy
Katrina J
KJ
Tamborlane
William V
WV
D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D008875:Middle Aged; D018670:Monitoring, Ambulatory / Q000379:methods*; D018579:Patient Selection
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
Patient Educ Couns. 2007 Sep;68(1):10-5
17582726
Diabetes Care. 1995 Jun;18(6):754-60
7555499
Pediatr Diabetes. 2008 Apr;9(2):142-7
18221427
Diabetes Educ. 2009 May-Jun;35(3):465-75
19321802
N Engl J Med. 2008 Oct 2;359(14):1464-76
18779236
Ann Intern Med. 2006 Apr 4;144(7):465-74
16585660
Diabetes. 2008 Dec;57(12):3169-76
19033403
Diabetes Technol Ther. 2008 Aug;10(4):310-21
18828243
Clin Chem. 1999 Oct;45(10):1833-41
10508131
Diabetes Care. 2008 Jan;31(1):81-6
17934153
Diabetologia. 2009 Jul;52(7):1250-7
19396424
Diabetes Care. 2005 May;28(5):1101-6
15855573
Diabetes Care. 2009 Aug;32(8):1378-83
19429875
J Pediatr Psychol. 1990 Oct;15(5):633-41
2283572